The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction (Endo-Olfact)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Julie van Waterschoot
- Phone Number: +32477910294
- Email: julie.vanwaterschoot@kuleuven.be
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Recruiting
- KU Leuven
-
Contact:
- Julie van Waterschoot
- Phone Number: 0477910294
- Email: julie.vanwaterschoot@kuleuven.be
-
Contact:
- Julie van Waterschoot
-
Contact:
- Laura Van Gerven, Professor
-
-
-
-
Hessen
-
Frankfurt, Hessen, Germany, 69
- Active, not recruiting
- Max Planck Research Unit for Neurogenetics
-
-
-
-
Zuid-Holland
-
Leiden, Zuid-Holland, Netherlands, 10702
- Not yet recruiting
- Leiden University Medical Center
-
Contact:
- Maarten Kleijwegt
- Phone Number: 0477910294
- Email: m.c.kleijwegt@lumc.nl
-
Contact:
- Maarten Kleijwegt
-
Contact:
- Marco Verstegen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients scheduled for endoscopic endonasal skull base surgery
Exclusion Criteria:
- Pre-existing anosmia
- Patients has a history of previous endoscopic endonasal skull base surgery
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of olfactory dysfunction
Time Frame: From enrollment to the last evaluation 6 months postoperatively
|
From enrollment to the last evaluation 6 months postoperatively
|
|
Incidence of trigeminal dysfunction
Time Frame: From enrollment to the last evaluation 6 months postoperatively
|
From enrollment to the last evaluation 6 months postoperatively
|
|
Etiology of olfactory and trigeminal dysfunction following endoscopic endonasal skull base surgery
Time Frame: Until the end of study (at 3 years)
|
Until the end of study (at 3 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Risk factors for olfactory dysfunction following endoscopic endonasal skull base surgery
Time Frame: From enrollment to the last evaluation 6 months postoperatively
|
Parameters such as smoking history, allergies, age, gender, co-morbidities will be investigated as possible covariates
|
From enrollment to the last evaluation 6 months postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Bone Diseases
- Musculoskeletal Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Bone Neoplasms
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Central Nervous System Neoplasms
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Adamantinoma
- Meningioma
- Adenoma
- Pituitary Neoplasms
- Pituitary Diseases
- Craniopharyngioma
Other Study ID Numbers
Other Study ID Numbers
- S69823
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.